Literature DB >> 15470525

[Italian consensus on Eular 2003 recommendations for the treatment of knee osteoarthritis].

L Punzi1, B Canesi, M Carrabba, M A Cimmino, L Frizziero, G Lapadula, G Arioli, M Chevallard, F Cozzi, C Cricelli, A Fioravanti, S Giannini, F Iannone, G Leardini, A Mannoni, R Meliconi, V Modena, L Molfetta, V Monteleone, T Nava, L Parente, E Paresce, P Patrignani, R Ramonda, F Salaffi, A Spadaro, R Marcolongo.   

Abstract

The recommendations for the management of osteoarthritis (OA) of the knee firstly proposed by the EULAR in 2000, have been updated in 2003. One of the most important objectives of the expert charged to provide these recommendations was their dissemination. Thus, the information generated may be used by each individual country to produce their own set of management guidelines and algorithms for treatment in primary care. The Italian Society of Rheumatology (SIR) and the Italian League against Rheumatism (LIMAR) have organised a Consensus on the EULAR recommendations 2003 with the aim to analyse their acceptability and applicability according to our own experience and local situations in the Italy. The results of this Consensus have demonstrated that a large majority of the EULAR recommendations are endorsed by the Italian experts. Furthermore, the final document of the Italian Consensus clearly indicated the need that specialists involved in the management of knee OA strongly encourage the dissemination of the EULAR 2003 recommendations also in Italy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15470525     DOI: 10.4081/reumatismo.2004.190

Source DB:  PubMed          Journal:  Reumatismo        ISSN: 0048-7449


  2 in total

Review 1.  EULAR recommendations for knee and hip osteoarthritis: a critique of the methodology.

Authors:  W Zhang; M Doherty
Journal:  Br J Sports Med       Date:  2006-08       Impact factor: 13.800

Review 2.  Highly purified chondroitin sulfate: a literature review on clinical efficacy and pharmacoeconomic aspects in osteoarthritis treatment.

Authors:  Jean-Yves Reginster; Nicola Veronese
Journal:  Aging Clin Exp Res       Date:  2020-07-07       Impact factor: 3.636

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.